Histoblast M Tablet contains Bilastine 20mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Bilastine is a second-generation H1 antihistamine that selectively inhibits peripheral histamine receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and pruritus associated with allergic rhinitis and urticaria. Montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus secretion, and airway edema, making it beneficial in managing asthma and allergic rhinitis. The combination of these two agents in Histoblast M Tablet offers a dual mechanism of action, targeting both histamine and leukotriene pathways, which enhances symptomatic control in patients with seasonal or perennial allergic rhinitis and asthma. This formulation is typically administered once daily, providing sustained relief with a favorable safety profile and minimal sedation compared to first-generation antihistamines. Histoblast M Tablet should be used under medical supervision, particularly in patients with hepatic or renal impairment, and is contraindicated in individuals with known hypersensitivity to its components. It is important to adhere to prescribed dosages and consult healthcare providers for any adverse reactions or drug interactions.